Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 3,196	$ 4,079	$ 6,675	$ 8,411
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	786	2,071	2,807	4,285
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,410	$ 2,008	$ 3,868	$ 4,126